chartexchange

IBRX261023C00009000
IBRX Oct 23 2026 9.00 Call
optionOPRA

EODOct 16, 2026
0.50USD-60.000%(-0.75)168Vol243OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
9
Expiration
Oct 23, 2026
DTE
3d
Moneyness
OTM
Intrinsic
$0.00
IBRX 9 Call Across Expirations
ExpirationDTELastChangeVolOpen Int
Oct 23, 20263d$0.50-60.00%168243
Oct 30, 202610d$0.74-50.67%4371,164
Nov 6, 202617d$1.10-26.17%1864
Nov 13, 202624d$1.19-38.02%512
Nov 20, 202631d$1.10-38.89%405,958
Nov 27, 202638d$1.86+0.00%1010
Dec 18, 202659d$2.00+0.00%400400
Jan 15, 202787d$1.87-25.20%646,730
Mar 19, 2027150d$2.30-24.09%73428
Apr 16, 2027178d$3.40-12.82%142
May 21, 2027213d$4.00+65.29%114
IBRX Nearby Strikes · Oct 23, 2026
StrikeLastChangeVolOpen IntMoneyness
6 C$4.53+0.00%11ITM
6.5 C——00ITM
7 C$3.00+0.00%1010ITM
7.5 C$2.47-14.83%1324ITM
8 C$2.17+3.33%1123ITM
8.5 C$1.82-4.71%1195OTM
9 C$0.50-60.00%168243OTM
9.5 C$0.28-65.00%263438OTM
10 C$0.18-55.00%1,1991,985OTM
10.5 C$0.15-57.14%2271,477OTM
11 C$0.05-80.00%541,377OTM
11.5 C$0.05-82.14%7143OTM
12 C$0.05-50.00%125190OTM
IBRX Profile

immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.